Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Telix Pharmaceuticals to Acquire European Production Facility
MELBOURNE (Australia) and BRUSSELS (Belgium) – Oct. 3, 2019 - Telix Pharmaceuticals Ltd is pleased to announce that it has...
Telix Cleared to Commence Renal Cancer Imaging Study in Japan
Melbourne (Australia) and Kyoto (Japan) – 30 August 2019. Telix Pharmaceuticals Limited today announced the completion of a Clinical Trial...
FDA Pre-NDA Meeting Outcomes : TLX591-CDx (illumet™)
MELBOURNE (Australia) and INDIANAPOLIS (USA) – 28 August 2019. Telix had a pre-NDA meeting with the United States Food and...
Appendix 4D and Financial Report for half-year to 30 June 19
MELBOURNE (Australia) Aug. 22, 2019 - Appendix 4D Half-year report for the six months ended 30 June 2019